Close
The work of the TMSRG brings together cutting edge technology with precision and stratified medicine for the benefit of patients. We specialise in using extreme deep phenotyping (proteomics, metabolomics and lipidomics) to find new drug targets, elucidate disease mechanisms, identify new biomarkers and develop new tests for the NHS and industrial drug trials. The TMSRG are headed by Prof Kevin Mills and Dr Wendy Heywood.
Discovery: Our approach is to work closely with our medical colleagues to firstly deep phenotype smaller cohorts of well-defined clinical samples to identify pathways and critical proteins, metabolites and lipids for further study.
Confirmation: These pathways and molecules are then validated statistically by their development into multiplexed and high throughput analyses that are capable of analysing large cohorts of samples i.e. deep phenotyping on smaller well clinically defined patients followed by validation on large sample cohorts.
The advantage of this streamlined strategy is that potential disease mechanisms and altered pathways are confirmed quicker and more efficiently as being therapeutic targets worthy of further evaluation. In addition, the development of any targeted proteomic, metabolomic or lipid mass spectral assays to confirm any findings are translated to triple quadrupole based mass spectrometers and are performed to NHS/ Industrial standards. Therefore, these tests can seamlessly be translated into the clinical service at GOSH/NHNN who have the same platform of mass spectrometers as our research based technology.
